In 2019, the US Department of Health and Human Services (HHS) announced the “Ending the HIV Epidemic: A Plan for America” initiative. As part of that initiative, CDC, RTI Health Solutions (RTI-HS), and RTI International researchers performed a study on allocating funds for HIV prevention to...
HTAi symposium highlights - value assessment in Alzheimer's disease research should incorporate the breadth of relevant outcomes
Antibiotics have played a significant role in expanding life expectancy over the last 100 years. However, bacteria have evolved and developed the genetic machinery to adapt and resist antimicrobials, threatening to make antibiotics ineffective – known as antimicrobial resistance (AMR). The...
it also explains Markov and Budget Impact Analysis modeling and discusses the advantages and disadvantages of using retrospective databases and real-world data
RTI Health Solutions (RTI-HS) is pleased to announce that we are a certified facilitator for the Medtech Early Technical Assessment (META) tool developed by the National Institute for Health and Care Excellence (NICE). META is an online platform designed to provide a budget-friendly value...
A first-time study determined that just 30.6% of US 17-year-olds had received all vaccines
RTI Health Solutions is pleased to announce that Brett Hauber, PhD, Senior Economist and VP, Health Preference Assessment, has been appointed as Senior Fellow in the RTI Fellow Program.
We're excited to reach this milestone in our journey
RTI Health Solutions (RTI-HS) is proud to announce that two of our researchers have been awarded fellowship status by the International Society for Pharmacoepidemiology (ISPE) Board of Directors. Both Alicia Gilsenan, PhD, RPh, and Andrea Margulis, MD, ScD, will be acknowledged as new FISPE...
On August 31, 2020, the FDA released its draft guidance titled “Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation.”
The Author Awards Program, now in its 17th year, was established by the RTI Fellows as a way to recognize staff members
In advance of an approved COVID-19 vaccine, the European Medicines Agency (EMA) has commissioned research to monitor any vaccine that is approved for its safety and effectiveness in clinical practice.
Multiple myeloma (MM) is a type of blood cancer that occurs in our body’s plasma cells. Rapidly reproducing, cancerous cells collect in bone marrow and crowd out healthy cells. Myeloma cells produce antibodies that, instead of fighting off infection, cause problems such as kidney and bone damage...
Many biologic treatments are available for controlling symptoms of psoriasis. The treatments have varying purchase costs, dosing amounts and frequency, and real-world use. Therefore, understanding the total costs of these treatments to insurers can be difficult.
Experts on our Patient-Centered Outcomes Assessment (PCOA) team collaborated to create this best practices document to help research teams mitigate some of the impacts of COVID-19 on the collection and use of clinical outcome assessment (COA) data.
Combination expands offering of real-world data/real-world evidence (RWD/RWE) to the world’s leading pharmaceutical and biotech companies
by RTI-HS Health Economists Molly Purser, PhD and Naoko Ronquest, PhD
Healthy women over the age of 75 years might not benefit from continuing breast cancer screening.
RTI Health Solutions' parent company, RTI International, has been recognized by Forbes Magazine for its diverse workplace. The annual 2020 list of the ‘Best Employers for Diversity’—released each year by Forbes—ranked RTI #277 out of 500 companies based on a survey of nearly 60,000 employees at...
Recurring ear infections in children are not only frustrating and painful–they can also cause serious complications. If antibiotics do not successfully treat an ear infection or if infections continue to occur, a physician may recommend the insertion of ear tubes. Until now that has required the...
Answers to key questions about the communication of information for unapproved products as well as unapproved uses of approved products.
Pharmacoepidemiology, now in its sixth edition, provides comprehensive guidance available for anyone needing up-to-date information in pharmacoepidemiology.
We have conducted a review of publicly available information on scientific advice services offered by HTA bodies
Health technology assessments are becoming more influential in countries where payers were traditionally not using value-based pricing methods for pricing negotiations.